Vicore Pharma Holding AB (OSTO:VICO BTA) Change In Receivables : kr-6.84 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Change In Receivables?

Vicore Pharma Holding AB's change in receivables for the quarter that ended in Mar. 2025 was kr13.39 Mil. It means Vicore Pharma Holding AB's Accounts Receivable declined by kr13.39 Mil from Dec. 2024 to Mar. 2025 .

Vicore Pharma Holding AB's change in receivables for the fiscal year that ended in Dec. 2024 was kr-35.60 Mil. It means Vicore Pharma Holding AB's Accounts Receivable increased by kr35.60 Mil from Dec. 2023 to Dec. 2024 .

Vicore Pharma Holding AB's Accounts Receivable for the quarter that ended in Mar. 2025 was kr0.87 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vicore Pharma Holding AB's Days Sales Outstanding for the three months ended in Mar. 2025 was 89.31.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vicore Pharma Holding AB's liquidation value for the three months ended in Mar. 2025 was kr986.34 Mil.

Vicore Pharma Holding AB Change In Receivables Historical Data

The historical data trend for Vicore Pharma Holding AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Change In Receivables Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-3.87

-0.34

-1.60

-4.28

-35.60

Vicore Pharma Holding AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-15.37	17.49	-17.36	-20.36	13.39

Vicore Pharma Holding AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-6.84 Mil.

Vicore Pharma Holding AB (OSTO:VICO BTA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vicore Pharma Holding AB's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.873	/	0.892	*	91
=	89.31

2. In Ben Graham's calculation of liquidation value, Vicore Pharma Holding AB's accounts receivable are only considered to be worth 75% of book value:

Vicore Pharma Holding AB's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1048.763	-	63.078	+	0.75 * 0.873	+	0.5 * 0
=	986.34

Vicore Pharma Holding AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VICO:Sweden

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines